Version history

{
  "content_md": "## Overview\n\nThis hypothesis proposes that **[Alzheimer's disease](/diseases/alzheimers-disease) pathology originates in the [hippocampus](/brain-regions/hippocampus) and subsequently spreads to temporal, parietal, and prefrontal association cortices via transneuronal transmission of [misfolded proteins](/proteins/misfolded-proteins) along the projection pathways of affected [neurons](/cell-types/neurons)**. [@raj2015]\n\n**Type:** Mechanistic Proposal\n\n**Confidence:** Strong\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease), [Primary age-related tauopathy](/diseases/primary-age-related-tauopathy)\n\n## Mechanistic Model\n\nflowchart TD\n    subgraph Initiation_Sites\n        A[\"Entorhinal Cortex\"] --> B[\"Hippocampus (CA1)\"]\n        B --> C[\"Subiculum\"]\n    end\n\n    subgraph Prion_Like_Propagation\n        D[\"Tau Misfolding\"] --> E[\"Synaptic Release\"]\n        E --> F[\"Axonal Transport\"]\n        F --> G[\"Transsynaptic Transfer\"]\n        G --> H[\"Recipient Neuron Uptake\"]\n        H --> I[\"Tau Aggregation\"]\n    end\n\n    subgraph Connectivity_Dependent_Spread\n        J[\"Hippocampal Output\"] --> K[\"Posterior Cingulate\"]\n        J --> L[\"Temporal Association Cortex\"]\n        K --> M[\"Parietal Cortex\"]\n        L --> M\n        M --> N[\"Prefrontal Cortex\"]\n    end\n\n    subgraph Clinical_Progression\n        I --> O[\"Neuronal Dysfunction\"]\n        N --> O\n        O --> P[\"Network Breakdown\"]\n        P --> Q[\"Cognitive Decline\"]\n        Q --> R[\"Memory Loss -> -> Global Cognition\"]\n    end\n\n    subgraph Therapeutic_Targets\n        S[\"Anti-Tau Antibodies\"]\n        T[\"Tau Aggregation Inhibitors\"]\n        S --> E\n        T --> I\n    end\n\n    style A fill:#e3f2fd\n    style B fill:#e3f2fd\n    style D fill:#fff3e0\n    style I fill:#ffcdd2\n    style Q fill:#ff5252\n    style S fill:#c8e6c9\n    style T fill:#c8e6c9\n\n## Mechanistic Details\n\nBased on [Braak model](/mechanisms/braak-staging) of neurofibrillary tau tangle progression (stages I-VI) and longitudinal [MRI](/technologies/mri) studies showing progression follows vulnerable fiber pathways rather than spatial proximity. This hypothesis posits a [prion-like propagation](/mechanisms/prion-like-propagation) mechanism where misfolded [tau](/proteins/tau) proteins transmit across synapses to connected neurons.\n\n### Transneuronal Transmission Mechanisms\n\nThe transneuronal spread of [tau pathology](/mechanisms/tau-pathology) involves several interconnected mechanisms:\n\n1. **Synaptic transmission**: [Tau](/proteins/tau) proteins can be released at synapses and taken up by connected neurons\n2. **Axonal transport**: Misfolded tau propagates along microtubules within axons\n3. **Exosome-mediated transfer**: Extracellular vesicles facilitate interneuronal tau transmission\n4. **Network vulnerability**: [Brain regions](/brain-regions) with high connectivity show earlier and more severe pathology\n\n### Braak Staging Progression\n\nThe classic [Braak staging](/mechanisms/braak-staging) system describes the hierarchical spread of neurofibrillary tangles:\n\n- **Stages I-II (Transentorhinal)**: Pathology confined to the [transentorhinal](/brain-regions/entorhinal-cortex) and [entorhinal cortices](/brain-regions/entorhinal-cortex)\n- **Stages III-IV (Limbic)**: Spread to limbic structures including [hippocampus](/brain-regions/hippocampus) and [amygdala](/brain-regions/amygdala)\n- **Stages V-VI (Isocortical)**: Widespread involvement of association cortices\n\n### Molecular Mechanisms of Propagation\n\nThe prion-like spread of tau involves:\n\n1. **Template-directed misfolding**: Pathological tau serves as a template for normal tau conversion\n2. **Oligomeric intermediates**: Soluble tau oligomers are the transmissible species\n3. **Synaptic vesicle release**: Tau associates with synaptic vesicles for transsynaptic passage\n4. **Microtubule disruption**: Pathological tau destabilizes axonal transport\n5. **Neuronal vulnerability**: High-connectivity neurons are preferentially affected\n\n### Support Vector Machine Classification\n\nRecent computational approaches using support vector machine (SVM) classifiers have validated the staging model, showing that spatial patterns of tau pathology can be accurately classified into [Braak stages](/mechanisms/braak-staging) based on regional involvement patterns. [@raj2015]\n\n## Evidence Assessment\n\n### Evidence Breakdown\n\n| Evidence Type | Support Level | Key Studies |\n|--------------|---------------|-------------|\n| Neuropathology | Strong | Braak & Braak 1991, extensive postmortem validation |\n| Neuroimaging | Strong | PET tau tracers, longitudinal MRI |\n| Animal Models | Strong | AAV-tau injection, seeding experiments |\n| Human Tissue | Strong | Autopsy studies, biopsy validation |\n| Computational | Strong | SVM classification, network analysis |\n\n### Confidence Level: **Strong**\n\nThe evidence for hippocampal origin and transneuronal spread of [AD](/diseases/alzheimers-disease) pathology is robust:\n- Consistent neuropathological staging across thousands of brains\n- Validated by modern neuroimaging techniques\n- Experimental proof of prion-like tau transmission in animal models\n\n### Testability Score: **10/10**\n\n- [PET imaging](/techniques/pet) with tau tracers (Flortaucipir, others)\n- Longitudinal MRI tracking regional atrophy\n- CSF and blood biomarkers for tau species\n- Postmortem neuropathological examination\n\n### Therapeutic Potential Score: **9/10**\n\nTau propagation represents a promising therapeutic target:\n- Anti-tau antibodies in clinical trials\n- Tau aggregation inhibitors in development\n- Small molecules targeting tau secretion\n\n### Key Supporting Studies\n\n1. [Braak & Braak (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z) - Neurofibrillary changes staging\n2. [Raj et al. (2015)](https://doi.org/10.1016/j.celrep.2014.12.034) - SVM-based classification of tau pathology stages\n3. [Cho et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/) - Tau PET and Braak staging correlation\n4. [Schubert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/) - Network-based tau spread modeling\n\n### Key Challenges\n\n- Distinguishing primary vs. secondary tau propagation\n- Identifying the trigger of initial tau misfolding in entorhinal cortex\n- Determining why some networks are preferentially vulnerable\n\n## Key Entities\n\n### Brain Regions\n\n[hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [transentorhinal cortex](/brain-regions/entorhinal-cortex), [amygdala](/brain-regions/amygdala), [temporal cortex](/brain-regions/temporal-cortex), [parietal cortex](/brain-regions/parietal-cortex), [prefrontal cortex](/brain-regions/prefrontal-cortex), [posterior cingulate](/brain-regions/posterior-cingulate)\n\n### Proteins & Molecules\n\n[misfolded proteins](/proteins/misfolded-proteins), [tau](/proteins/tau), [amyloid-beta](/proteins/amyloid-beta), [phosphorylated tau](/biomarkers/p-tau), [tau oligomers](/biomarkers/tau-oligomers)\n\n### Related Mechanisms\n\n[tau pathology](/mechanisms/tau-pathology), [prion-like propagation](/mechanisms/prion-like-propagation), [synaptic transmission](/mechanisms/synaptic-transmission), [brain connectivity network](/mechanisms/connectivity), [Braak staging](/mechanisms/braak-staging), [neurofibrillary tangles](/mechanisms/neurofibrillary-tangles)\n\n## Experimental Approaches\n\n### Current Methods\n\n1. **Tau PET neuroimaging**: Flortaucipir (AV-1451) and second-generation tracers\n2. **Longitudinal MRI**: Track atrophy patterns over time\n3. **CSF biomarkers**: p-tau181, p-tau217, p-tau231\n4. **Postmortem neuropathology**: Braak staging verification\n\n### Emerging Techniques\n\n1. **Blood-based tau biomarkers**: p-tau217, p-tau181 assays\n2. **Super-resolution microscopy**: Tau oligomer visualization\n3. **iPSC-derived neurons**: Patient-specific propagation models\n\n## Therapeutic Implications\n\n### Therapeutic Strategies\n\n| Approach | Target | Status | Clinical Trials |\n|----------|--------|--------|-----------------|\n| Anti-tau antibodies | Extracellular tau | Phase 2/3 | NCT05338424, NCT04640008 |\n| Tau aggregation inhibitors | Intracellular tau oligomers | Phase 1 | NCT05539110 |\n| Tau-targeted vaccines | Passive/active immunization | Phase 1/2 | NCT05417147, NCT05239842 |\n| Synaptic transmission blockers | Tau release at synapses | Preclinical | - |\n| Kinase inhibitors | Tau phosphorylation reduction | Phase 1 | NCT04832138 |\n| Microtubule stabilizers | Normal tau function restoration | Preclinical | - |\n| Antibody delivery methods | Enhanced brain penetration | Preclinical | - |\n\n### Related Therapeutics\n\n- [Lecanemab](/therapeutics/lecanemab) — Approved anti-amyloid antibody with effects on tau\n- [Donanemab](/therapeutics/donaneumab) — Anti-tau antibody in late-stage trials\n- [Anti-tau antibodies in development](/therapeutics/anti-tau-therapeutics)\n- [Tau aggregation inhibitors](/therapeutics/tau-aggregation-inhibitors)\n\n### Clinical Trial Landscape\n\nThe therapeutic targeting of tau propagation has accelerated significantly:\n\n1. **Anti-tau monoclonal antibodies**: Multiple candidates in Phase 2/3 trials\n2. **Small molecule inhibitors**: Tau aggregation inhibitors entering clinical testing\n3. **Active vaccination**: Tau-based vaccines showing promise in early trials\n4. **Gene therapy approaches**: AAV-delivered anti-tau constructs in development\n5. **Combination therapies**: Amyloid removal + tau propagation blocking\n\n## Related Hypotheses\n\n- [Tau Hyperphosphorylation in AD](/hypotheses/tau-hyperphosphorylation-ad)\n- [Amyloid-Tau Synergy Hypothesis](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi)\n- [Prion-like Protein Propagation](/hypotheses/prion-like-protein-propagation)\n- [Aβ as Sine Qua Non for Tau Spread](/hypotheses/aβ-sine-qua-non-tau-spread)\n\n## References\n\n1. [Braak & Braak, Neurofibrillary changes (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z)\n2. [Raj et al., SVM-based classification of tau pathology stages (2015)](https://doi.org/10.1016/j.celrep.2014.12.034)\n3. [Cho et al., Tau PET and Braak staging correlation (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/)\n4. [Schubert et al., Network-based tau spread modeling (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)\n5. [Jucker & Walker, Prion-like propagation of tau (2013)](https://pubmed.ncbi.nlm.nih.gov/24088950/)\n6. [Polanco et al., Tau exosome transmission (2018)](https://pubmed.ncbi.nlm.nih.gov/30567890/)\n7. [Vergara et al., Axonal tau transport mechanisms (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)\n8. [Furman et al., Tau and network dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)\n9. [Ayton et al., Brain connectivity and tau spread (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)\n10. [Young et al., Tau PET staging in preclinical AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)\n11. [Thal et al., Phases of Aβ deposition (2020)](https://pubmed.ncbi.nlm.nih.gov/32035176/)\n12. [Hyman et al., National Institute on Aging-AD consensus criteria (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)\n13. [Jagust & Landau, Temporal sequence of AD biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)\n14. [Veitch et al., Alzheimer's Disease Neuroimaging Initiative findings (2023)](https://pubmed.ncbi.nlm.nih.gov/38098765/)\n15. [Scheltens et al., Alzheimer's disease: timeline and therapeutic approaches (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)\n16. [Masters et al., Alzheimer's disease (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)\n\n## Evidence Rubric\n\n### Confidence Level: **Strong**\n\nThe evidence for hippocampal origin and transneuronal spread of AD pathology is robust and represents one of the best-established frameworks in neurodegeneration research:\n\n- Consistent neuropathological staging across thousands of brains over 30+ years\n- Validated by modern neuroimaging techniques (PET, MRI)\n- Experimental proof of prion-like tau transmission in animal models\n- Strong correlation between staging and clinical phenotype\n\n### Evidence Type Breakdown\n\n| Evidence Type | Support Level | Key Studies |\n|--------------|---------------|-------------|\n| Neuropathology | Strong | Braak & Braak 1991, extensive postmortem validation across decades |\n| Neuroimaging | Strong | PET tau tracers (Flortaucipir), longitudinal MRI, functional connectivity |\n| Genetic | Strong | MAPT mutations, AD genetic risk factors |\n| Animal Models | Strong | AAV-tau injection, seeding experiments, prion-like transmission |\n| Human Tissue | Strong | Autopsy studies, biopsy validation |\n| Computational | Strong | SVM classification, network analysis, predictive modeling |\n| Biomarker | Strong | CSF p-tau181/217/231, blood-based tau biomarkers |\n| Clinical | Strong | Correlation with cognitive decline, staging predictions |\n\n### Testability Score: **10/10**\n\nThis hypothesis is among the most testable in all of neurodegenerative disease research:\n\n- **Tau PET imaging**: Flortaucipir (AV-1451) and second-generation tracers enable in vivo visualization\n- **Longitudinal MRI**: Track regional atrophy patterns over time\n- **CSF biomarkers**: p-tau181, p-tau217, p-tau231 provide biochemical confirmation\n- **Blood biomarkers**: p-tau217, p-tau181 assays for scalable screening\n- **Postmortem neuropathology**: Braak staging verification remains gold standard\n\n### Therapeutic Potential Score: **9/10**\n\nTau propagation represents one of the most promising therapeutic targets in AD:\n\n- Anti-tau antibodies in clinical trials (Lecanemab has received approval)\n- Tau aggregation inhibitors in development\n- Small molecules targeting tau secretion\n- Vaccination strategies (active and passive immunization)\n- Combination therapy targeting multiple propagation steps\n\n### Key Supporting Studies\n\n1. [Braak & Braak (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z) — Original neurofibrillary changes staging system\n2. [Raj et al. (2015)](https://doi.org/10.1016/j.celrep.2014.12.034) — SVM-based classification of tau pathology stages\n3. [Cho et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/) — Tau PET and Braak staging correlation\n4. [Schubert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/) — Network-based tau spread modeling\n5. [Jucker & Walker (2013)](https://pubmed.ncbi.nlm.nih.gov/24088950/) — Prion-like propagation of tau\n6. [Matthews et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/) — Network spread patterns in early AD\n7. [Chen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/) — Transneuronal tau spread in human tissue\n\n### Key Challenges and Contradictions\n\n- **Primary vs. secondary tau propagation**: Distinguishing whether tau spread is cause or consequence\n- **Initial trigger identification**: What initiates tau misfolding in entorhinal cortex?\n- **Network selectivity**: Why are some networks preferentially vulnerable?\n- **Amyloid independence**: Understanding tau propagation in non-amyloid cases\n- **Therapeutic timing**: Optimal intervention window for anti-tau therapies\n\n## Molecular Mechanisms of Tau Propagation\n\n### Template-Directed Misfolding\n\nThe prion-like propagation of tau involves several critical molecular steps:\n\n1. **Nucleation-dependent polymerization**: Pathological tau serves as a template for normal tau conversion\n2. **Oligomeric intermediates**: Soluble tau oligomers are the transmissible species\n3. **Conformational change**: Pathological tau adopts beta-sheet rich structure\n4. **Strain diversity**: Different tau conformations produce distinct clinical phenotypes\n\n### Transsynaptic Passage Mechanisms\n\nTau propagates between neurons through multiple mechanisms:\n\n1. **Synaptic vesicle release**: Tau associates with synaptic vesicles for transsynaptic passage\n2. **Exosome-mediated transfer**: Extracellular vesicles facilitate interneuronal transmission\n3. **Direct membrane crossing**: Tau can penetrate membranes under certain conditions\n4. **Microtubule-based transport**: Propagating tau moves along axonal microtubules\n\n### Cellular Clearance Mechanisms\n\nThe brain has multiple pathways for tau clearance:\n\n1. **Autophagy-lysosomal pathway**: Macroautophagy and CMA degrade tau\n2. **Ubiquitin-proteasome system**: Degrades soluble tau species\n3. **Astrocyte uptake**: Astrocytes can internalize and degrade extracellular tau\n4. **Microglial phagocytosis**: Microglia clear tau from the extracellular space\n5. **Blood-brain barrier export**: Active transport removes tau from CNS\n\n## Network-Level Analysis\n\n### Vulnerability Patterns\n\nThe selective vulnerability of specific brain networks reflects multiple factors:\n\n1. **Metabolic demand**: High metabolic rate increases vulnerability to oxidative stress\n2. **Synaptic density**: More synapses provide more transmission sites for tau propagation\n3. **Connectivity degree**: Highly connected regions receive more pathological tau inputs\n4. **Amyloid-beta deposition**: Aβ-affected regions show earlier tau accumulation\n5. **Tau metabolism**: Regional differences in clearance capacity affect vulnerability\n6. **Neuronal subtype**: Specific neuron types (e.g., layer II entorhinal neurons) are selectively vulnerable\n\n### Default Mode Network Special Susceptibility\n\nThe Default Mode Network (DMN) is particularly vulnerable to tau pathology because:\n\n- Highest Aβ deposition occurs in precuneus and posterior cingulate\n- High connectivity facilitates tau propagation between hubs\n- Metabolic demands increase oxidative stress and mitochondrial dysfunction\n- Layer II entorhinal cortex neurons have unique vulnerability to early tau changes\n- Subiculum and CA1 hippocampal subregions show early tau burden\n\n### Network Propagation Flowchart\n\nflowchart TD\n    subgraph Initiation_Phase\n        A[\"Entorhinal Cortex<br/>(Layer II)\"] -->|\"Tau misfolding\"| B[\"Perforant path<br/>projection\"]\n        B -->|\"Axonal transport\"| C[\"Dentate Gyrus<br/>granule cells\"]\n        C -->|\"Synaptic release\"| D[\"CA3 pyramidal<br/>neurons\"]\n    end\n\n    subgraph Propagation_Phase\n        D -->|\"Network spread\"| E[\"CA1<br/>subiculum\"]\n        E -->|\"Output pathways\"| F[\"Subiculum -><br/>Posterior Cingulate\"]\n        E -->|\"Output pathways\"| G[\"Subiculum -><br/>Entorhinal feedback\"]\n        F -->|\"Connectivity\"| H[\"Precuneus\"]\n        G --> H\n        H -->|\"Association fibers\"| I[\"Parietal Cortex\"]\n        I -->|\"Higher-order<br/>networks\"| J[\"Prefrontal Cortex\"]\n    end\n\n    subgraph Clinical_Manifestation\n        D -->|\"Memory circuit<br/>dysfunction\"| K[\"Episodic Memory<br/>Impairment\"]\n        F -->|\"Default mode<br/>disruption\"| L[\"Self-referential<br/>Processing deficits\"]\n        J -->|\"Executive function<br/>impairment\"| M[\"Cognitive Control<br/>Decline\"]\n        K --> N\n        L --> N\n        M --> N[\"Global Cognitive<br/>Decline\"]\n    end\n\n    style A fill:#ffcdd2\n    style K fill:#ffcdd2\n    style N fill:#ff6666\n    style J fill:#ffeebb\n\n## Biomarker Correlations\n\n### CSF Biomarker Trajectories\n\n| Biomarker | Preclinical | Prodromal AD | Dementia | Notes |\n|-----------|-------------|--------------|----------|-------|\n| Aβ42/Aβ40 | Decreased | Significantly decreased | Lowest | Reflects plaque accumulation |\n| t-tau | Normal | Increased | Highly elevated | Non-specific neuronal injury |\n| p-tau181 | Normal | Moderately elevated | Highly elevated | Specific to tau pathology |\n| p-tau217 | Normal | Highly elevated | Highly elevated | Best early detection marker |\n| p-tau231 | Elevated | Highly elevated | Highly elevated | Earliest detectable change |\n| NfL | Normal | Moderately elevated | Highly elevated | Axonal injury marker |\n\n### Blood-Based Biomarker Advances\n\nRecent advances in blood-based biomarkers enable scalable detection:\n\n1. **p-tau217**: Highly sensitive to early tau changes, correlates strongly with Braak staging\n2. **p-tau181**: Widely validated, available on multiple clinical platforms\n3. **p-tau231**: Detects very early tau pathology in entorhinal cortex before symptoms\n4. **Neurofilament light (NfL)**: General marker of axonal injury, non-specific but useful\n5. **GFAP**: Astrocyte activation marker, correlates with amyloid burden\n\n### Imaging Biomarker Progression\n\n| Modality | Target | Preclinical | Prodromal | Dementia |\n|----------|--------|-------------|-----------|----------|\n| Amyloid PET | Aβ plaques | Positive in precuneus | Widespread | Dense throughout |\n| Tau PET | NFT | Negative/trace | Positivity in EC | Cortical spread |\n| FDG-PET | Metabolism | Normal | Posterior cingulate hypometabolism | Widespread hypometabolism |\n| MRI | Atrophy | Normal | Hippocampal atrophy | Cortical thinning |\n| rsfMRI | Connectivity | Normal | DMN connectivity decline | Global network disruption |\n\n## Conclusion\n\nThe hypothesis that Alzheimer's disease pathology originates in the hippocampus and subsequently spreads via transneuronal transmission provides a coherent framework that integrates:\n\n- Observed neuropathological staging patterns across thousands of cases\n- Neuroimaging findings demonstrating regional progression over time\n- Biomarker trajectories showing sequential changes across disease stages\n- Network-level vulnerability factors explaining selective susceptibility\n- Therapeutic targeting opportunities for disease modification\n\nThis understanding enables early detection through biomarker screening, accurate disease staging for clinical trials, and targeted therapeutic development aimed at blocking tau propagation in its earliest stages before widespread neurodegeneration occurs.\n\n## Background\n\nThe study of Alzheimer's Disease Pathology Originates In The Hippocampus And Subsequently Spreads has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Braak Staging](/mechanisms/braak-staging)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)",
  "entity_type": "hypothesis"
}

{
  "content_md": "## Overview\n\nThis hypothesis proposes that **[Alzheimer's disease](/diseases/alzheimers-disease) pathology originates in the [hippocampus](/brain-regions/hippocampus) and subsequently spreads to temporal, parietal, and prefrontal association cortices via transneuronal transmission of [misfolded proteins](/proteins/misfolded-proteins) along the projection pathways of affected [neurons](/cell-types/neurons)**. [@raj2015]\n\n**Type:** Mechanistic Proposal\n\n**Confidence:** Strong\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease), [Primary age-related tauopathy](/diseases/primary-age-related-tauopathy)\n\n## Mechanistic Model\n\n```mermaid\nflowchart TD\n    subgraph Initiation_Sites\n        A[\"Entorhinal Cortex\"] --> B[\"Hippocampus (CA1)\"]\n        B --> C[\"Subiculum\"]\n    end\n\n    subgraph Prion_Like_Propagation\n        D[\"Tau Misfolding\"] --> E[\"Synaptic Release\"]\n        E --> F[\"Axonal Transport\"]\n        F --> G[\"Transsynaptic Transfer\"]\n        G --> H[\"Recipient Neuron Uptake\"]\n        H --> I[\"Tau Aggregation\"]\n    end\n\n    subgraph Connectivity_Dependent_Spread\n        J[\"Hippocampal Output\"] --> K[\"Posterior Cingulate\"]\n        J --> L[\"Temporal Association Cortex\"]\n        K --> M[\"Parietal Cortex\"]\n        L --> M\n        M --> N[\"Prefrontal Cortex\"]\n    end\n\n    subgraph Clinical_Progression\n        I --> O[\"Neuronal Dysfunction\"]\n        N --> O\n        O --> P[\"Network Breakdown\"]\n        P --> Q[\"Cognitive Decline\"]\n        Q --> R[\"Memory Loss -> -> Global Cognition\"]\n    end\n\n    subgraph Therapeutic_Targets\n        S[\"Anti-Tau Antibodies\"]\n        T[\"Tau Aggregation Inhibitors\"]\n        S --> E\n        T --> I\n    end\n\n    style A fill:#e3f2fd\n    style B fill:#e3f2fd\n    style D fill:#fff3e0\n    style I fill:#ffcdd2\n    style Q fill:#ff5252\n    style S fill:#c8e6c9\n    style T fill:#c8e6c9\n```\n\n## Mechanistic Details\n\nBased on [Braak model](/mechanisms/braak-staging) of neurofibrillary tau tangle progression (stages I-VI) and longitudinal [MRI](/technologies/mri) studies showing progression follows vulnerable fiber pathways rather than spatial proximity. This hypothesis posits a [prion-like propagation](/mechanisms/prion-like-propagation) mechanism where misfolded [tau](/proteins/tau) proteins transmit across synapses to connected neurons.\n\n### Transneuronal Transmission Mechanisms\n\nThe transneuronal spread of [tau pathology](/mechanisms/tau-pathology) involves several interconnected mechanisms:\n\n1. **Synaptic transmission**: [Tau](/proteins/tau) proteins can be released at synapses and taken up by connected neurons\n2. **Axonal transport**: Misfolded tau propagates along microtubules within axons\n3. **Exosome-mediated transfer**: Extracellular vesicles facilitate interneuronal tau transmission\n4. **Network vulnerability**: [Brain regions](/brain-regions) with high connectivity show earlier and more severe pathology\n\n### Braak Staging Progression\n\nThe classic [Braak staging](/mechanisms/braak-staging) system describes the hierarchical spread of neurofibrillary tangles:\n\n- **Stages I-II (Transentorhinal)**: Pathology confined to the [transentorhinal](/brain-regions/entorhinal-cortex) and [entorhinal cortices](/brain-regions/entorhinal-cortex)\n- **Stages III-IV (Limbic)**: Spread to limbic structures including [hippocampus](/brain-regions/hippocampus) and [amygdala](/brain-regions/amygdala)\n- **Stages V-VI (Isocortical)**: Widespread involvement of association cortices\n\n### Molecular Mechanisms of Propagation\n\nThe prion-like spread of tau involves:\n\n1. **Template-directed misfolding**: Pathological tau serves as a template for normal tau conversion\n2. **Oligomeric intermediates**: Soluble tau oligomers are the transmissible species\n3. **Synaptic vesicle release**: Tau associates with synaptic vesicles for transsynaptic passage\n4. **Microtubule disruption**: Pathological tau destabilizes axonal transport\n5. **Neuronal vulnerability**: High-connectivity neurons are preferentially affected\n\n### Support Vector Machine Classification\n\nRecent computational approaches using support vector machine (SVM) classifiers have validated the staging model, showing that spatial patterns of tau pathology can be accurately classified into [Braak stages](/mechanisms/braak-staging) based on regional involvement patterns. [@raj2015]\n\n## Evidence Assessment\n\n### Evidence Breakdown\n\n| Evidence Type | Support Level | Key Studies |\n|--------------|---------------|-------------|\n| Neuropathology | Strong | Braak & Braak 1991, extensive postmortem validation |\n| Neuroimaging | Strong | PET tau tracers, longitudinal MRI |\n| Animal Models | Strong | AAV-tau injection, seeding experiments |\n| Human Tissue | Strong | Autopsy studies, biopsy validation |\n| Computational | Strong | SVM classification, network analysis |\n\n### Confidence Level: **Strong**\n\nThe evidence for hippocampal origin and transneuronal spread of [AD](/diseases/alzheimers-disease) pathology is robust:\n- Consistent neuropathological staging across thousands of brains\n- Validated by modern neuroimaging techniques\n- Experimental proof of prion-like tau transmission in animal models\n\n### Testability Score: **10/10**\n\n- [PET imaging](/techniques/pet) with tau tracers (Flortaucipir, others)\n- Longitudinal MRI tracking regional atrophy\n- CSF and blood biomarkers for tau species\n- Postmortem neuropathological examination\n\n### Therapeutic Potential Score: **9/10**\n\nTau propagation represents a promising therapeutic target:\n- Anti-tau antibodies in clinical trials\n- Tau aggregation inhibitors in development\n- Small molecules targeting tau secretion\n\n### Key Supporting Studies\n\n1. [Braak & Braak (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z) - Neurofibrillary changes staging\n2. [Raj et al. (2015)](https://doi.org/10.1016/j.celrep.2014.12.034) - SVM-based classification of tau pathology stages\n3. [Cho et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/) - Tau PET and Braak staging correlation\n4. [Schubert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/) - Network-based tau spread modeling\n\n### Key Challenges\n\n- Distinguishing primary vs. secondary tau propagation\n- Identifying the trigger of initial tau misfolding in entorhinal cortex\n- Determining why some networks are preferentially vulnerable\n\n## Key Entities\n\n### Brain Regions\n\n[hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [transentorhinal cortex](/brain-regions/entorhinal-cortex), [amygdala](/brain-regions/amygdala), [temporal cortex](/brain-regions/temporal-cortex), [parietal cortex](/brain-regions/parietal-cortex), [prefrontal cortex](/brain-regions/prefrontal-cortex), [posterior cingulate](/brain-regions/posterior-cingulate)\n\n### Proteins & Molecules\n\n[misfolded proteins](/proteins/misfolded-proteins), [tau](/proteins/tau), [amyloid-beta](/proteins/amyloid-beta), [phosphorylated tau](/biomarkers/p-tau), [tau oligomers](/biomarkers/tau-oligomers)\n\n### Related Mechanisms\n\n[tau pathology](/mechanisms/tau-pathology), [prion-like propagation](/mechanisms/prion-like-propagation), [synaptic transmission](/mechanisms/synaptic-transmission), [brain connectivity network](/mechanisms/connectivity), [Braak staging](/mechanisms/braak-staging), [neurofibrillary tangles](/mechanisms/neurofibrillary-tangles)\n\n## Experimental Approaches\n\n### Current Methods\n\n1. **Tau PET neuroimaging**: Flortaucipir (AV-1451) and second-generation tracers\n2. **Longitudinal MRI**: Track atrophy patterns over time\n3. **CSF biomarkers**: p-tau181, p-tau217, p-tau231\n4. **Postmortem neuropathology**: Braak staging verification\n\n### Emerging Techniques\n\n1. **Blood-based tau biomarkers**: p-tau217, p-tau181 assays\n2. **Super-resolution microscopy**: Tau oligomer visualization\n3. **iPSC-derived neurons**: Patient-specific propagation models\n\n## Therapeutic Implications\n\n### Therapeutic Strategies\n\n| Approach | Target | Status | Clinical Trials |\n|----------|--------|--------|-----------------|\n| Anti-tau antibodies | Extracellular tau | Phase 2/3 | NCT05338424, NCT04640008 |\n| Tau aggregation inhibitors | Intracellular tau oligomers | Phase 1 | NCT05539110 |\n| Tau-targeted vaccines | Passive/active immunization | Phase 1/2 | NCT05417147, NCT05239842 |\n| Synaptic transmission blockers | Tau release at synapses | Preclinical | - |\n| Kinase inhibitors | Tau phosphorylation reduction | Phase 1 | NCT04832138 |\n| Microtubule stabilizers | Normal tau function restoration | Preclinical | - |\n| Antibody delivery methods | Enhanced brain penetration | Preclinical | - |\n\n### Related Therapeutics\n\n- [Lecanemab](/therapeutics/lecanemab) — Approved anti-amyloid antibody with effects on tau\n- [Donanemab](/therapeutics/donaneumab) — Anti-tau antibody in late-stage trials\n- [Anti-tau antibodies in development](/therapeutics/anti-tau-therapeutics)\n- [Tau aggregation inhibitors](/therapeutics/tau-aggregation-inhibitors)\n\n### Clinical Trial Landscape\n\nThe therapeutic targeting of tau propagation has accelerated significantly:\n\n1. **Anti-tau monoclonal antibodies**: Multiple candidates in Phase 2/3 trials\n2. **Small molecule inhibitors**: Tau aggregation inhibitors entering clinical testing\n3. **Active vaccination**: Tau-based vaccines showing promise in early trials\n4. **Gene therapy approaches**: AAV-delivered anti-tau constructs in development\n5. **Combination therapies**: Amyloid removal + tau propagation blocking\n\n## Related Hypotheses\n\n- [Tau Hyperphosphorylation in AD](/hypotheses/tau-hyperphosphorylation-ad)\n- [Amyloid-Tau Synergy Hypothesis](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi)\n- [Prion-like Protein Propagation](/hypotheses/prion-like-protein-propagation)\n- [Aβ as Sine Qua Non for Tau Spread](/hypotheses/aβ-sine-qua-non-tau-spread)\n\n## References\n\n1. [Braak & Braak, Neurofibrillary changes (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z)\n2. [Raj et al., SVM-based classification of tau pathology stages (2015)](https://doi.org/10.1016/j.celrep.2014.12.034)\n3. [Cho et al., Tau PET and Braak staging correlation (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/)\n4. [Schubert et al., Network-based tau spread modeling (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)\n5. [Jucker & Walker, Prion-like propagation of tau (2013)](https://pubmed.ncbi.nlm.nih.gov/24088950/)\n6. [Polanco et al., Tau exosome transmission (2018)](https://pubmed.ncbi.nlm.nih.gov/30567890/)\n7. [Vergara et al., Axonal tau transport mechanisms (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)\n8. [Furman et al., Tau and network dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)\n9. [Ayton et al., Brain connectivity and tau spread (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)\n10. [Young et al., Tau PET staging in preclinical AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)\n11. [Thal et al., Phases of Aβ deposition (2020)](https://pubmed.ncbi.nlm.nih.gov/32035176/)\n12. [Hyman et al., National Institute on Aging-AD consensus criteria (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)\n13. [Jagust & Landau, Temporal sequence of AD biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)\n14. [Veitch et al., Alzheimer's Disease Neuroimaging Initiative findings (2023)](https://pubmed.ncbi.nlm.nih.gov/38098765/)\n15. [Scheltens et al., Alzheimer's disease: timeline and therapeutic approaches (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)\n16. [Masters et al., Alzheimer's disease (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)\n\n## Evidence Rubric\n\n### Confidence Level: **Strong**\n\nThe evidence for hippocampal origin and transneuronal spread of AD pathology is robust and represents one of the best-established frameworks in neurodegeneration research:\n\n- Consistent neuropathological staging across thousands of brains over 30+ years\n- Validated by modern neuroimaging techniques (PET, MRI)\n- Experimental proof of prion-like tau transmission in animal models\n- Strong correlation between staging and clinical phenotype\n\n### Evidence Type Breakdown\n\n| Evidence Type | Support Level | Key Studies |\n|--------------|---------------|-------------|\n| Neuropathology | Strong | Braak & Braak 1991, extensive postmortem validation across decades |\n| Neuroimaging | Strong | PET tau tracers (Flortaucipir), longitudinal MRI, functional connectivity |\n| Genetic | Strong | MAPT mutations, AD genetic risk factors |\n| Animal Models | Strong | AAV-tau injection, seeding experiments, prion-like transmission |\n| Human Tissue | Strong | Autopsy studies, biopsy validation |\n| Computational | Strong | SVM classification, network analysis, predictive modeling |\n| Biomarker | Strong | CSF p-tau181/217/231, blood-based tau biomarkers |\n| Clinical | Strong | Correlation with cognitive decline, staging predictions |\n\n### Testability Score: **10/10**\n\nThis hypothesis is among the most testable in all of neurodegenerative disease research:\n\n- **Tau PET imaging**: Flortaucipir (AV-1451) and second-generation tracers enable in vivo visualization\n- **Longitudinal MRI**: Track regional atrophy patterns over time\n- **CSF biomarkers**: p-tau181, p-tau217, p-tau231 provide biochemical confirmation\n- **Blood biomarkers**: p-tau217, p-tau181 assays for scalable screening\n- **Postmortem neuropathology**: Braak staging verification remains gold standard\n\n### Therapeutic Potential Score: **9/10**\n\nTau propagation represents one of the most promising therapeutic targets in AD:\n\n- Anti-tau antibodies in clinical trials (Lecanemab has received approval)\n- Tau aggregation inhibitors in development\n- Small molecules targeting tau secretion\n- Vaccination strategies (active and passive immunization)\n- Combination therapy targeting multiple propagation steps\n\n### Key Supporting Studies\n\n1. [Braak & Braak (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z) — Original neurofibrillary changes staging system\n2. [Raj et al. (2015)](https://doi.org/10.1016/j.celrep.2014.12.034) — SVM-based classification of tau pathology stages\n3. [Cho et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/) — Tau PET and Braak staging correlation\n4. [Schubert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/) — Network-based tau spread modeling\n5. [Jucker & Walker (2013)](https://pubmed.ncbi.nlm.nih.gov/24088950/) — Prion-like propagation of tau\n6. [Matthews et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/) — Network spread patterns in early AD\n7. [Chen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/) — Transneuronal tau spread in human tissue\n\n### Key Challenges and Contradictions\n\n- **Primary vs. secondary tau propagation**: Distinguishing whether tau spread is cause or consequence\n- **Initial trigger identification**: What initiates tau misfolding in entorhinal cortex?\n- **Network selectivity**: Why are some networks preferentially vulnerable?\n- **Amyloid independence**: Understanding tau propagation in non-amyloid cases\n- **Therapeutic timing**: Optimal intervention window for anti-tau therapies\n\n## Molecular Mechanisms of Tau Propagation\n\n### Template-Directed Misfolding\n\nThe prion-like propagation of tau involves several critical molecular steps:\n\n1. **Nucleation-dependent polymerization**: Pathological tau serves as a template for normal tau conversion\n2. **Oligomeric intermediates**: Soluble tau oligomers are the transmissible species\n3. **Conformational change**: Pathological tau adopts beta-sheet rich structure\n4. **Strain diversity**: Different tau conformations produce distinct clinical phenotypes\n\n### Transsynaptic Passage Mechanisms\n\nTau propagates between neurons through multiple mechanisms:\n\n1. **Synaptic vesicle release**: Tau associates with synaptic vesicles for transsynaptic passage\n2. **Exosome-mediated transfer**: Extracellular vesicles facilitate interneuronal transmission\n3. **Direct membrane crossing**: Tau can penetrate membranes under certain conditions\n4. **Microtubule-based transport**: Propagating tau moves along axonal microtubules\n\n### Cellular Clearance Mechanisms\n\nThe brain has multiple pathways for tau clearance:\n\n1. **Autophagy-lysosomal pathway**: Macroautophagy and CMA degrade tau\n2. **Ubiquitin-proteasome system**: Degrades soluble tau species\n3. **Astrocyte uptake**: Astrocytes can internalize and degrade extracellular tau\n4. **Microglial phagocytosis**: Microglia clear tau from the extracellular space\n5. **Blood-brain barrier export**: Active transport removes tau from CNS\n\n## Network-Level Analysis\n\n### Vulnerability Patterns\n\nThe selective vulnerability of specific brain networks reflects multiple factors:\n\n1. **Metabolic demand**: High metabolic rate increases vulnerability to oxidative stress\n2. **Synaptic density**: More synapses provide more transmission sites for tau propagation\n3. **Connectivity degree**: Highly connected regions receive more pathological tau inputs\n4. **Amyloid-beta deposition**: Aβ-affected regions show earlier tau accumulation\n5. **Tau metabolism**: Regional differences in clearance capacity affect vulnerability\n6. **Neuronal subtype**: Specific neuron types (e.g., layer II entorhinal neurons) are selectively vulnerable\n\n### Default Mode Network Special Susceptibility\n\nThe Default Mode Network (DMN) is particularly vulnerable to tau pathology because:\n\n- Highest Aβ deposition occurs in precuneus and posterior cingulate\n- High connectivity facilitates tau propagation between hubs\n- Metabolic demands increase oxidative stress and mitochondrial dysfunction\n- Layer II entorhinal cortex neurons have unique vulnerability to early tau changes\n- Subiculum and CA1 hippocampal subregions show early tau burden\n\n### Network Propagation Flowchart\n\n```mermaid\nflowchart TD\n    subgraph Initiation_Phase\n        A[\"Entorhinal Cortex<br/>(Layer II)\"] -->|\"Tau misfolding\"| B[\"Perforant path<br/>projection\"]\n        B -->|\"Axonal transport\"| C[\"Dentate Gyrus<br/>granule cells\"]\n        C -->|\"Synaptic release\"| D[\"CA3 pyramidal<br/>neurons\"]\n    end\n\n    subgraph Propagation_Phase\n        D -->|\"Network spread\"| E[\"CA1<br/>subiculum\"]\n        E -->|\"Output pathways\"| F[\"Subiculum -><br/>Posterior Cingulate\"]\n        E -->|\"Output pathways\"| G[\"Subiculum -><br/>Entorhinal feedback\"]\n        F -->|\"Connectivity\"| H[\"Precuneus\"]\n        G --> H\n        H -->|\"Association fibers\"| I[\"Parietal Cortex\"]\n        I -->|\"Higher-order<br/>networks\"| J[\"Prefrontal Cortex\"]\n    end\n\n    subgraph Clinical_Manifestation\n        D -->|\"Memory circuit<br/>dysfunction\"| K[\"Episodic Memory<br/>Impairment\"]\n        F -->|\"Default mode<br/>disruption\"| L[\"Self-referential<br/>Processing deficits\"]\n        J -->|\"Executive function<br/>impairment\"| M[\"Cognitive Control<br/>Decline\"]\n        K --> N\n        L --> N\n        M --> N[\"Global Cognitive<br/>Decline\"]\n    end\n\n    style A fill:#ffcdd2\n    style K fill:#ffcdd2\n    style N fill:#ff6666\n    style J fill:#ffeebb\n```\n\n## Biomarker Correlations\n\n### CSF Biomarker Trajectories\n\n| Biomarker | Preclinical | Prodromal AD | Dementia | Notes |\n|-----------|-------------|--------------|----------|-------|\n| Aβ42/Aβ40 | Decreased | Significantly decreased | Lowest | Reflects plaque accumulation |\n| t-tau | Normal | Increased | Highly elevated | Non-specific neuronal injury |\n| p-tau181 | Normal | Moderately elevated | Highly elevated | Specific to tau pathology |\n| p-tau217 | Normal | Highly elevated | Highly elevated | Best early detection marker |\n| p-tau231 | Elevated | Highly elevated | Highly elevated | Earliest detectable change |\n| NfL | Normal | Moderately elevated | Highly elevated | Axonal injury marker |\n\n### Blood-Based Biomarker Advances\n\nRecent advances in blood-based biomarkers enable scalable detection:\n\n1. **p-tau217**: Highly sensitive to early tau changes, correlates strongly with Braak staging\n2. **p-tau181**: Widely validated, available on multiple clinical platforms\n3. **p-tau231**: Detects very early tau pathology in entorhinal cortex before symptoms\n4. **Neurofilament light (NfL)**: General marker of axonal injury, non-specific but useful\n5. **GFAP**: Astrocyte activation marker, correlates with amyloid burden\n\n### Imaging Biomarker Progression\n\n| Modality | Target | Preclinical | Prodromal | Dementia |\n|----------|--------|-------------|-----------|----------|\n| Amyloid PET | Aβ plaques | Positive in precuneus | Widespread | Dense throughout |\n| Tau PET | NFT | Negative/trace | Positivity in EC | Cortical spread |\n| FDG-PET | Metabolism | Normal | Posterior cingulate hypometabolism | Widespread hypometabolism |\n| MRI | Atrophy | Normal | Hippocampal atrophy | Cortical thinning |\n| rsfMRI | Connectivity | Normal | DMN connectivity decline | Global network disruption |\n\n## Conclusion\n\nThe hypothesis that Alzheimer's disease pathology originates in the hippocampus and subsequently spreads via transneuronal transmission provides a coherent framework that integrates:\n\n- Observed neuropathological staging patterns across thousands of cases\n- Neuroimaging findings demonstrating regional progression over time\n- Biomarker trajectories showing sequential changes across disease stages\n- Network-level vulnerability factors explaining selective susceptibility\n- Therapeutic targeting opportunities for disease modification\n\nThis understanding enables early detection through biomarker screening, accurate disease staging for clinical trials, and targeted therapeutic development aimed at blocking tau propagation in its earliest stages before widespread neurodegeneration occurs.\n\n## Background\n\nThe study of Alzheimer's Disease Pathology Originates In The Hippocampus And Subsequently Spreads has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Braak Staging](/mechanisms/braak-staging)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)",
  "entity_type": "hypothesis"
}

{
  "content_md": "## Overview\n\nThis hypothesis proposes that **[Alzheimer's disease](/diseases/alzheimers-disease) pathology originates in the [hippocampus](/brain-regions/hippocampus) and subsequently spreads to temporal, parietal, and prefrontal association cortices via transneuronal transmission of [misfolded proteins](/proteins/misfolded-proteins) along the projection pathways of affected [neurons](/cell-types/neurons)**. [@raj2015]\n\n**Type:** Mechanistic Proposal\n\n**Confidence:** Strong\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease), [Primary age-related tauopathy](/diseases/primary-age-related-tauopathy)\n\n## Mechanistic Model\n\n```mermaid\nflowchart TD\n    subgraph Initiation_Sites\n        A[\"Entorhinal Cortex\"] --> B[\"Hippocampus (CA1)\"]\n        B --> C[\"Subiculum\"]\n    end\n\n    subgraph Prion_Like_Propagation\n        D[\"Tau Misfolding\"] --> E[\"Synaptic Release\"]\n        E --> F[\"Axonal Transport\"]\n        F --> G[\"Transsynaptic Transfer\"]\n        G --> H[\"Recipient Neuron Uptake\"]\n        H --> I[\"Tau Aggregation\"]\n    end\n\n    subgraph Connectivity_Dependent_Spread\n        J[\"Hippocampal Output\"] --> K[\"Posterior Cingulate\"]\n        J --> L[\"Temporal Association Cortex\"]\n        K --> M[\"Parietal Cortex\"]\n        L --> M\n        M --> N[\"Prefrontal Cortex\"]\n    end\n\n    subgraph Clinical_Progression\n        I --> O[\"Neuronal Dysfunction\"]\n        N --> O\n        O --> P[\"Network Breakdown\"]\n        P --> Q[\"Cognitive Decline\"]\n        Q --> R[\"Memory Loss -> -> Global Cognition\"]\n    end\n\n    subgraph Therapeutic_Targets\n        S[\"Anti-Tau Antibodies\"]\n        T[\"Tau Aggregation Inhibitors\"]\n        S --> E\n        T --> I\n    end\n\n    style A fill:#e3f2fd\n    style B fill:#e3f2fd\n    style D fill:#fff3e0\n    style I fill:#ffcdd2\n    style Q fill:#ff5252\n    style S fill:#c8e6c9\n    style T fill:#c8e6c9\n```\n\n## Mechanistic Details\n\nBased on [Braak model](/mechanisms/braak-staging) of neurofibrillary tau tangle progression (stages I-VI) and longitudinal [MRI](/technologies/mri) studies showing progression follows vulnerable fiber pathways rather than spatial proximity. This hypothesis posits a [prion-like propagation](/mechanisms/prion-like-propagation) mechanism where misfolded [tau](/proteins/tau) proteins transmit across synapses to connected neurons.\n\n### Transneuronal Transmission Mechanisms\n\nThe transneuronal spread of [tau pathology](/mechanisms/tau-pathology) involves several interconnected mechanisms:\n\n1. **Synaptic transmission**: [Tau](/proteins/tau) proteins can be released at synapses and taken up by connected neurons\n2. **Axonal transport**: Misfolded tau propagates along microtubules within axons\n3. **Exosome-mediated transfer**: Extracellular vesicles facilitate interneuronal tau transmission\n4. **Network vulnerability**: [Brain regions](/brain-regions) with high connectivity show earlier and more severe pathology\n\n### Braak Staging Progression\n\nThe classic [Braak staging](/mechanisms/braak-staging) system describes the hierarchical spread of neurofibrillary tangles:\n\n- **Stages I-II (Transentorhinal)**: Pathology confined to the [transentorhinal](/brain-regions/entorhinal-cortex) and [entorhinal cortices](/brain-regions/entorhinal-cortex)\n- **Stages III-IV (Limbic)**: Spread to limbic structures including [hippocampus](/brain-regions/hippocampus) and [amygdala](/brain-regions/amygdala)\n- **Stages V-VI (Isocortical)**: Widespread involvement of association cortices\n\n### Molecular Mechanisms of Propagation\n\nThe prion-like spread of tau involves:\n\n1. **Template-directed misfolding**: Pathological tau serves as a template for normal tau conversion\n2. **Oligomeric intermediates**: Soluble tau oligomers are the transmissible species\n3. **Synaptic vesicle release**: Tau associates with synaptic vesicles for transsynaptic passage\n4. **Microtubule disruption**: Pathological tau destabilizes axonal transport\n5. **Neuronal vulnerability**: High-connectivity neurons are preferentially affected\n\n### Support Vector Machine Classification\n\nRecent computational approaches using support vector machine (SVM) classifiers have validated the staging model, showing that spatial patterns of tau pathology can be accurately classified into [Braak stages](/mechanisms/braak-staging) based on regional involvement patterns. [@raj2015]\n\n## Evidence Assessment\n\n### Evidence Breakdown\n\n| Evidence Type | Support Level | Key Studies |\n|--------------|---------------|-------------|\n| Neuropathology | Strong | Braak & Braak 1991, extensive postmortem validation |\n| Neuroimaging | Strong | PET tau tracers, longitudinal MRI |\n| Animal Models | Strong | AAV-tau injection, seeding experiments |\n| Human Tissue | Strong | Autopsy studies, biopsy validation |\n| Computational | Strong | SVM classification, network analysis |\n\n### Confidence Level: **Strong**\n\nThe evidence for hippocampal origin and transneuronal spread of [AD](/diseases/alzheimers-disease) pathology is robust:\n- Consistent neuropathological staging across thousands of brains\n- Validated by modern neuroimaging techniques\n- Experimental proof of prion-like tau transmission in animal models\n\n### Testability Score: **10/10**\n\n- [PET imaging](/techniques/pet) with tau tracers (Flortaucipir, others)\n- Longitudinal MRI tracking regional atrophy\n- CSF and blood biomarkers for tau species\n- Postmortem neuropathological examination\n\n### Therapeutic Potential Score: **9/10**\n\nTau propagation represents a promising therapeutic target:\n- Anti-tau antibodies in clinical trials\n- Tau aggregation inhibitors in development\n- Small molecules targeting tau secretion\n\n### Key Supporting Studies\n\n1. [Braak & Braak (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z) - Neurofibrillary changes staging\n2. [Raj et al. (2015)](https://doi.org/10.1016/j.celrep.2014.12.034) - SVM-based classification of tau pathology stages\n3. [Cho et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/) - Tau PET and Braak staging correlation\n4. [Schubert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/) - Network-based tau spread modeling\n\n### Key Challenges\n\n- Distinguishing primary vs. secondary tau propagation\n- Identifying the trigger of initial tau misfolding in entorhinal cortex\n- Determining why some networks are preferentially vulnerable\n\n## Key Entities\n\n### Brain Regions\n\n[hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [transentorhinal cortex](/brain-regions/entorhinal-cortex), [amygdala](/brain-regions/amygdala), [temporal cortex](/brain-regions/temporal-cortex), [parietal cortex](/brain-regions/parietal-cortex), [prefrontal cortex](/brain-regions/prefrontal-cortex), [posterior cingulate](/brain-regions/posterior-cingulate)\n\n### Proteins & Molecules\n\n[misfolded proteins](/proteins/misfolded-proteins), [tau](/proteins/tau), [amyloid-beta](/proteins/amyloid-beta), [phosphorylated tau](/biomarkers/p-tau), [tau oligomers](/biomarkers/tau-oligomers)\n\n### Related Mechanisms\n\n[tau pathology](/mechanisms/tau-pathology), [prion-like propagation](/mechanisms/prion-like-propagation), [synaptic transmission](/mechanisms/synaptic-transmission), [brain connectivity network](/mechanisms/connectivity), [Braak staging](/mechanisms/braak-staging), [neurofibrillary tangles](/mechanisms/neurofibrillary-tangles)\n\n## Experimental Approaches\n\n### Current Methods\n\n1. **Tau PET neuroimaging**: Flortaucipir (AV-1451) and second-generation tracers\n2. **Longitudinal MRI**: Track atrophy patterns over time\n3. **CSF biomarkers**: p-tau181, p-tau217, p-tau231\n4. **Postmortem neuropathology**: Braak staging verification\n\n### Emerging Techniques\n\n1. **Blood-based tau biomarkers**: p-tau217, p-tau181 assays\n2. **Super-resolution microscopy**: Tau oligomer visualization\n3. **iPSC-derived neurons**: Patient-specific propagation models\n\n## Therapeutic Implications\n\n### Therapeutic Strategies\n\n| Approach | Target | Status | Clinical Trials |\n|----------|--------|--------|-----------------|\n| Anti-tau antibodies | Extracellular tau | Phase 2/3 | NCT05338424, NCT04640008 |\n| Tau aggregation inhibitors | Intracellular tau oligomers | Phase 1 | NCT05539110 |\n| Tau-targeted vaccines | Passive/active immunization | Phase 1/2 | NCT05417147, NCT05239842 |\n| Synaptic transmission blockers | Tau release at synapses | Preclinical | - |\n| Kinase inhibitors | Tau phosphorylation reduction | Phase 1 | NCT04832138 |\n| Microtubule stabilizers | Normal tau function restoration | Preclinical | - |\n| Antibody delivery methods | Enhanced brain penetration | Preclinical | - |\n\n### Related Therapeutics\n\n- [Lecanemab](/therapeutics/lecanemab) — Approved anti-amyloid antibody with effects on tau\n- [Donanemab](/therapeutics/donaneumab) — Anti-tau antibody in late-stage trials\n- [Anti-tau antibodies in development](/therapeutics/anti-tau-therapeutics)\n- [Tau aggregation inhibitors](/therapeutics/tau-aggregation-inhibitors)\n\n### Clinical Trial Landscape\n\nThe therapeutic targeting of tau propagation has accelerated significantly:\n\n1. **Anti-tau monoclonal antibodies**: Multiple candidates in Phase 2/3 trials\n2. **Small molecule inhibitors**: Tau aggregation inhibitors entering clinical testing\n3. **Active vaccination**: Tau-based vaccines showing promise in early trials\n4. **Gene therapy approaches**: AAV-delivered anti-tau constructs in development\n5. **Combination therapies**: Amyloid removal + tau propagation blocking\n\n## Related Hypotheses\n\n- [Tau Hyperphosphorylation in AD](/hypotheses/tau-hyperphosphorylation-ad)\n- [Amyloid-Tau Synergy Hypothesis](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi)\n- [Prion-like Protein Propagation](/hypotheses/prion-like-protein-propagation)\n- [Aβ as Sine Qua Non for Tau Spread](/hypotheses/aβ-sine-qua-non-tau-spread)\n\n## References\n\n1. [Braak & Braak, Neurofibrillary changes (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z)\n2. [Raj et al., SVM-based classification of tau pathology stages (2015)](https://doi.org/10.1016/j.celrep.2014.12.034)\n3. [Cho et al., Tau PET and Braak staging correlation (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/)\n4. [Schubert et al., Network-based tau spread modeling (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)\n5. [Jucker & Walker, Prion-like propagation of tau (2013)](https://pubmed.ncbi.nlm.nih.gov/24088950/)\n6. [Polanco et al., Tau exosome transmission (2018)](https://pubmed.ncbi.nlm.nih.gov/30567890/)\n7. [Vergara et al., Axonal tau transport mechanisms (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)\n8. [Furman et al., Tau and network dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)\n9. [Ayton et al., Brain connectivity and tau spread (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)\n10. [Young et al., Tau PET staging in preclinical AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)\n11. [Thal et al., Phases of Aβ deposition (2020)](https://pubmed.ncbi.nlm.nih.gov/32035176/)\n12. [Hyman et al., National Institute on Aging-AD consensus criteria (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)\n13. [Jagust & Landau, Temporal sequence of AD biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)\n14. [Veitch et al., Alzheimer's Disease Neuroimaging Initiative findings (2023)](https://pubmed.ncbi.nlm.nih.gov/38098765/)\n15. [Scheltens et al., Alzheimer's disease: timeline and therapeutic approaches (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)\n16. [Masters et al., Alzheimer's disease (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)\n\n## Evidence Rubric\n\n### Confidence Level: **Strong**\n\nThe evidence for hippocampal origin and transneuronal spread of AD pathology is robust and represents one of the best-established frameworks in neurodegeneration research:\n\n- Consistent neuropathological staging across thousands of brains over 30+ years\n- Validated by modern neuroimaging techniques (PET, MRI)\n- Experimental proof of prion-like tau transmission in animal models\n- Strong correlation between staging and clinical phenotype\n\n### Evidence Type Breakdown\n\n| Evidence Type | Support Level | Key Studies |\n|--------------|---------------|-------------|\n| Neuropathology | Strong | Braak & Braak 1991, extensive postmortem validation across decades |\n| Neuroimaging | Strong | PET tau tracers (Flortaucipir), longitudinal MRI, functional connectivity |\n| Genetic | Strong | MAPT mutations, AD genetic risk factors |\n| Animal Models | Strong | AAV-tau injection, seeding experiments, prion-like transmission |\n| Human Tissue | Strong | Autopsy studies, biopsy validation |\n| Computational | Strong | SVM classification, network analysis, predictive modeling |\n| Biomarker | Strong | CSF p-tau181/217/231, blood-based tau biomarkers |\n| Clinical | Strong | Correlation with cognitive decline, staging predictions |\n\n### Testability Score: **10/10**\n\nThis hypothesis is among the most testable in all of neurodegenerative disease research:\n\n- **Tau PET imaging**: Flortaucipir (AV-1451) and second-generation tracers enable in vivo visualization\n- **Longitudinal MRI**: Track regional atrophy patterns over time\n- **CSF biomarkers**: p-tau181, p-tau217, p-tau231 provide biochemical confirmation\n- **Blood biomarkers**: p-tau217, p-tau181 assays for scalable screening\n- **Postmortem neuropathology**: Braak staging verification remains gold standard\n\n### Therapeutic Potential Score: **9/10**\n\nTau propagation represents one of the most promising therapeutic targets in AD:\n\n- Anti-tau antibodies in clinical trials (Lecanemab has received approval)\n- Tau aggregation inhibitors in development\n- Small molecules targeting tau secretion\n- Vaccination strategies (active and passive immunization)\n- Combination therapy targeting multiple propagation steps\n\n### Key Supporting Studies\n\n1. [Braak & Braak (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z) — Original neurofibrillary changes staging system\n2. [Raj et al. (2015)](https://doi.org/10.1016/j.celrep.2014.12.034) — SVM-based classification of tau pathology stages\n3. [Cho et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/) — Tau PET and Braak staging correlation\n4. [Schubert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/) — Network-based tau spread modeling\n5. [Jucker & Walker (2013)](https://pubmed.ncbi.nlm.nih.gov/24088950/) — Prion-like propagation of tau\n6. [Matthews et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/) — Network spread patterns in early AD\n7. [Chen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/) — Transneuronal tau spread in human tissue\n\n### Key Challenges and Contradictions\n\n- **Primary vs. secondary tau propagation**: Distinguishing whether tau spread is cause or consequence\n- **Initial trigger identification**: What initiates tau misfolding in entorhinal cortex?\n- **Network selectivity**: Why are some networks preferentially vulnerable?\n- **Amyloid independence**: Understanding tau propagation in non-amyloid cases\n- **Therapeutic timing**: Optimal intervention window for anti-tau therapies\n\n## Molecular Mechanisms of Tau Propagation\n\n### Template-Directed Misfolding\n\nThe prion-like propagation of tau involves several critical molecular steps:\n\n1. **Nucleation-dependent polymerization**: Pathological tau serves as a template for normal tau conversion\n2. **Oligomeric intermediates**: Soluble tau oligomers are the transmissible species\n3. **Conformational change**: Pathological tau adopts beta-sheet rich structure\n4. **Strain diversity**: Different tau conformations produce distinct clinical phenotypes\n\n### Transsynaptic Passage Mechanisms\n\nTau propagates between neurons through multiple mechanisms:\n\n1. **Synaptic vesicle release**: Tau associates with synaptic vesicles for transsynaptic passage\n2. **Exosome-mediated transfer**: Extracellular vesicles facilitate interneuronal transmission\n3. **Direct membrane crossing**: Tau can penetrate membranes under certain conditions\n4. **Microtubule-based transport**: Propagating tau moves along axonal microtubules\n\n### Cellular Clearance Mechanisms\n\nThe brain has multiple pathways for tau clearance:\n\n1. **Autophagy-lysosomal pathway**: Macroautophagy and CMA degrade tau\n2. **Ubiquitin-proteasome system**: Degrades soluble tau species\n3. **Astrocyte uptake**: Astrocytes can internalize and degrade extracellular tau\n4. **Microglial phagocytosis**: Microglia clear tau from the extracellular space\n5. **Blood-brain barrier export**: Active transport removes tau from CNS\n\n## Network-Level Analysis\n\n### Vulnerability Patterns\n\nThe selective vulnerability of specific brain networks reflects multiple factors:\n\n1. **Metabolic demand**: High metabolic rate increases vulnerability to oxidative stress\n2. **Synaptic density**: More synapses provide more transmission sites for tau propagation\n3. **Connectivity degree**: Highly connected regions receive more pathological tau inputs\n4. **Amyloid-beta deposition**: Aβ-affected regions show earlier tau accumulation\n5. **Tau metabolism**: Regional differences in clearance capacity affect vulnerability\n6. **Neuronal subtype**: Specific neuron types (e.g., layer II entorhinal neurons) are selectively vulnerable\n\n### Default Mode Network Special Susceptibility\n\nThe Default Mode Network (DMN) is particularly vulnerable to tau pathology because:\n\n- Highest Aβ deposition occurs in precuneus and posterior cingulate\n- High connectivity facilitates tau propagation between hubs\n- Metabolic demands increase oxidative stress and mitochondrial dysfunction\n- Layer II entorhinal cortex neurons have unique vulnerability to early tau changes\n- Subiculum and CA1 hippocampal subregions show early tau burden\n\n### Network Propagation Flowchart\n\n```mermaid\nflowchart TD\n    subgraph Initiation_Phase\n        A[\"Entorhinal Cortex<br/>(Layer II)\"] -->|\"Tau misfolding\"| B[\"Perforant path<br/>projection\"]\n        B -->|\"Axonal transport\"| C[\"Dentate Gyrus<br/>granule cells\"]\n        C -->|\"Synaptic release\"| D[\"CA3 pyramidal<br/>neurons\"]\n    end\n\n    subgraph Propagation_Phase\n        D -->|\"Network spread\"| E[\"CA1<br/>subiculum\"]\n        E -->|\"Output pathways\"| F[\"Subiculum -><br/>Posterior Cingulate\"]\n        E -->|\"Output pathways\"| G[\"Subiculum -><br/>Entorhinal feedback\"]\n        F -->|\"Connectivity\"| H[\"Precuneus\"]\n        G --> H\n        H -->|\"Association fibers\"| I[\"Parietal Cortex\"]\n        I -->|\"Higher-order<br/>networks\"| J[\"Prefrontal Cortex\"]\n    end\n\n    subgraph Clinical_Manifestation\n        D -->|\"Memory circuit<br/>dysfunction\"| K[\"Episodic Memory<br/>Impairment\"]\n        F -->|\"Default mode<br/>disruption\"| L[\"Self-referential<br/>Processing deficits\"]\n        J -->|\"Executive function<br/>impairment\"| M[\"Cognitive Control<br/>Decline\"]\n        K --> N\n        L --> N\n        M --> N[\"Global Cognitive<br/>Decline\"]\n    end\n\n    style A fill:#ffcdd2\n    style K fill:#ffcdd2\n    style N fill:#ff6666\n    style J fill:#ffeebb\n```\n\n## Biomarker Correlations\n\n### CSF Biomarker Trajectories\n\n| Biomarker | Preclinical | Prodromal AD | Dementia | Notes |\n|-----------|-------------|--------------|----------|-------|\n| Aβ42/Aβ40 | Decreased | Significantly decreased | Lowest | Reflects plaque accumulation |\n| t-tau | Normal | Increased | Highly elevated | Non-specific neuronal injury |\n| p-tau181 | Normal | Moderately elevated | Highly elevated | Specific to tau pathology |\n| p-tau217 | Normal | Highly elevated | Highly elevated | Best early detection marker |\n| p-tau231 | Elevated | Highly elevated | Highly elevated | Earliest detectable change |\n| NfL | Normal | Moderately elevated | Highly elevated | Axonal injury marker |\n\n### Blood-Based Biomarker Advances\n\nRecent advances in blood-based biomarkers enable scalable detection:\n\n1. **p-tau217**: Highly sensitive to early tau changes, correlates strongly with Braak staging\n2. **p-tau181**: Widely validated, available on multiple clinical platforms\n3. **p-tau231**: Detects very early tau pathology in entorhinal cortex before symptoms\n4. **Neurofilament light (NfL)**: General marker of axonal injury, non-specific but useful\n5. **GFAP**: Astrocyte activation marker, correlates with amyloid burden\n\n### Imaging Biomarker Progression\n\n| Modality | Target | Preclinical | Prodromal | Dementia |\n|----------|--------|-------------|-----------|----------|\n| Amyloid PET | Aβ plaques | Positive in precuneus | Widespread | Dense throughout |\n| Tau PET | NFT | Negative/trace | Positivity in EC | Cortical spread |\n| FDG-PET | Metabolism | Normal | Posterior cingulate hypometabolism | Widespread hypometabolism |\n| MRI | Atrophy | Normal | Hippocampal atrophy | Cortical thinning |\n| rsfMRI | Connectivity | Normal | DMN connectivity decline | Global network disruption |\n\n## Conclusion\n\nThe hypothesis that Alzheimer's disease pathology originates in the hippocampus and subsequently spreads via transneuronal transmission provides a coherent framework that integrates:\n\n- Observed neuropathological staging patterns across thousands of cases\n- Neuroimaging findings demonstrating regional progression over time\n- Biomarker trajectories showing sequential changes across disease stages\n- Network-level vulnerability factors explaining selective susceptibility\n- Therapeutic targeting opportunities for disease modification\n\nThis understanding enables early detection through biomarker screening, accurate disease staging for clinical trials, and targeted therapeutic development aimed at blocking tau propagation in its earliest stages before widespread neurodegeneration occurs.\n\n## Background\n\nThe study of Alzheimer's Disease Pathology Originates In The Hippocampus And Subsequently Spreads has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Braak Staging](/mechanisms/braak-staging)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)",
  "entity_type": "hypothesis"
}

{
  "content_md": "## Overview\n\nThis hypothesis proposes that **[Alzheimer's disease](/diseases/alzheimers-disease) pathology originates in the [hippocampus](/brain-regions/hippocampus) and subsequently spreads to temporal, parietal, and prefrontal association cortices via transneuronal transmission of [misfolded proteins](/proteins/misfolded-proteins) along the projection pathways of affected [neurons](/cell-types/neurons)**. [@raj2015]\n\n**Type:** Mechanistic Proposal\n\n**Confidence:** Strong\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease), [Primary age-related tauopathy](/diseases/primary-age-related-tauopathy)\n\n## Mechanistic Model\n\n```mermaid\nflowchart TD\n    subgraph Initiation_Sites\n        A[\"Entorhinal Cortex\"] --> B[\"Hippocampus (CA1)\"]\n        B --> C[\"Subiculum\"]\n    end\n\n    subgraph Prion_Like_Propagation\n        D[\"Tau Misfolding\"] --> E[\"Synaptic Release\"]\n        E --> F[\"Axonal Transport\"]\n        F --> G[\"Transsynaptic Transfer\"]\n        G --> H[\"Recipient Neuron Uptake\"]\n        H --> I[\"Tau Aggregation\"]\n    end\n\n    subgraph Connectivity_Dependent_Spread\n        J[\"Hippocampal Output\"] --> K[\"Posterior Cingulate\"]\n        J --> L[\"Temporal Association Cortex\"]\n        K --> M[\"Parietal Cortex\"]\n        L --> M\n        M --> N[\"Prefrontal Cortex\"]\n    end\n\n    subgraph Clinical_Progression\n        I --> O[\"Neuronal Dysfunction\"]\n        N --> O\n        O --> P[\"Network Breakdown\"]\n        P --> Q[\"Cognitive Decline\"]\n        Q --> R[\"Memory Loss → → Global Cognition\"]\n    end\n\n    subgraph Therapeutic_Targets\n        S[\"Anti-Tau Antibodies\"]\n        T[\"Tau Aggregation Inhibitors\"]\n        S --> E\n        T --> I\n    end\n\n    style A fill:#e3f2fd\n    style B fill:#e3f2fd\n    style D fill:#fff3e0\n    style I fill:#ffcdd2\n    style Q fill:#ff5252\n    style S fill:#c8e6c9\n    style T fill:#c8e6c9\n```\n\n## Mechanistic Details\n\nBased on [Braak model](/mechanisms/braak-staging) of neurofibrillary tau tangle progression (stages I-VI) and longitudinal [MRI](/technologies/mri) studies showing progression follows vulnerable fiber pathways rather than spatial proximity. This hypothesis posits a [prion-like propagation](/mechanisms/prion-like-propagation) mechanism where misfolded [tau](/proteins/tau) proteins transmit across synapses to connected neurons.\n\n### Transneuronal Transmission Mechanisms\n\nThe transneuronal spread of [tau pathology](/mechanisms/tau-pathology) involves several interconnected mechanisms:\n\n1. **Synaptic transmission**: [Tau](/proteins/tau) proteins can be released at synapses and taken up by connected neurons\n2. **Axonal transport**: Misfolded tau propagates along microtubules within axons\n3. **Exosome-mediated transfer**: Extracellular vesicles facilitate interneuronal tau transmission\n4. **Network vulnerability**: [Brain regions](/brain-regions) with high connectivity show earlier and more severe pathology\n\n### Braak Staging Progression\n\nThe classic [Braak staging](/mechanisms/braak-staging) system describes the hierarchical spread of neurofibrillary tangles:\n\n- **Stages I-II (Transentorhinal)**: Pathology confined to the [transentorhinal](/brain-regions/entorhinal-cortex) and [entorhinal cortices](/brain-regions/entorhinal-cortex)\n- **Stages III-IV (Limbic)**: Spread to limbic structures including [hippocampus](/brain-regions/hippocampus) and [amygdala](/brain-regions/amygdala)\n- **Stages V-VI (Isocortical)**: Widespread involvement of association cortices\n\n### Molecular Mechanisms of Propagation\n\nThe prion-like spread of tau involves:\n\n1. **Template-directed misfolding**: Pathological tau serves as a template for normal tau conversion\n2. **Oligomeric intermediates**: Soluble tau oligomers are the transmissible species\n3. **Synaptic vesicle release**: Tau associates with synaptic vesicles for transsynaptic passage\n4. **Microtubule disruption**: Pathological tau destabilizes axonal transport\n5. **Neuronal vulnerability**: High-connectivity neurons are preferentially affected\n\n### Support Vector Machine Classification\n\nRecent computational approaches using support vector machine (SVM) classifiers have validated the staging model, showing that spatial patterns of tau pathology can be accurately classified into [Braak stages](/mechanisms/braak-staging) based on regional involvement patterns. [@raj2015]\n\n## Evidence Assessment\n\n### Evidence Breakdown\n\n| Evidence Type | Support Level | Key Studies |\n|--------------|---------------|-------------|\n| Neuropathology | Strong | Braak & Braak 1991, extensive postmortem validation |\n| Neuroimaging | Strong | PET tau tracers, longitudinal MRI |\n| Animal Models | Strong | AAV-tau injection, seeding experiments |\n| Human Tissue | Strong | Autopsy studies, biopsy validation |\n| Computational | Strong | SVM classification, network analysis |\n\n### Confidence Level: **Strong**\n\nThe evidence for hippocampal origin and transneuronal spread of [AD](/diseases/alzheimers-disease) pathology is robust:\n- Consistent neuropathological staging across thousands of brains\n- Validated by modern neuroimaging techniques\n- Experimental proof of prion-like tau transmission in animal models\n\n### Testability Score: **10/10**\n\n- [PET imaging](/techniques/pet) with tau tracers (Flortaucipir, others)\n- Longitudinal MRI tracking regional atrophy\n- CSF and blood biomarkers for tau species\n- Postmortem neuropathological examination\n\n### Therapeutic Potential Score: **9/10**\n\nTau propagation represents a promising therapeutic target:\n- Anti-tau antibodies in clinical trials\n- Tau aggregation inhibitors in development\n- Small molecules targeting tau secretion\n\n### Key Supporting Studies\n\n1. [Braak & Braak (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z) - Neurofibrillary changes staging\n2. [Raj et al. (2015)](https://doi.org/10.1016/j.celrep.2014.12.034) - SVM-based classification of tau pathology stages\n3. [Cho et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/) - Tau PET and Braak staging correlation\n4. [Schubert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/) - Network-based tau spread modeling\n\n### Key Challenges\n\n- Distinguishing primary vs. secondary tau propagation\n- Identifying the trigger of initial tau misfolding in entorhinal cortex\n- Determining why some networks are preferentially vulnerable\n\n## Key Entities\n\n### Brain Regions\n\n[hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [transentorhinal cortex](/brain-regions/entorhinal-cortex), [amygdala](/brain-regions/amygdala), [temporal cortex](/brain-regions/temporal-cortex), [parietal cortex](/brain-regions/parietal-cortex), [prefrontal cortex](/brain-regions/prefrontal-cortex), [posterior cingulate](/brain-regions/posterior-cingulate)\n\n### Proteins & Molecules\n\n[misfolded proteins](/proteins/misfolded-proteins), [tau](/proteins/tau), [amyloid-beta](/proteins/amyloid-beta), [phosphorylated tau](/biomarkers/p-tau), [tau oligomers](/biomarkers/tau-oligomers)\n\n### Related Mechanisms\n\n[tau pathology](/mechanisms/tau-pathology), [prion-like propagation](/mechanisms/prion-like-propagation), [synaptic transmission](/mechanisms/synaptic-transmission), [brain connectivity network](/mechanisms/connectivity), [Braak staging](/mechanisms/braak-staging), [neurofibrillary tangles](/mechanisms/neurofibrillary-tangles)\n\n## Experimental Approaches\n\n### Current Methods\n\n1. **Tau PET neuroimaging**: Flortaucipir (AV-1451) and second-generation tracers\n2. **Longitudinal MRI**: Track atrophy patterns over time\n3. **CSF biomarkers**: p-tau181, p-tau217, p-tau231\n4. **Postmortem neuropathology**: Braak staging verification\n\n### Emerging Techniques\n\n1. **Blood-based tau biomarkers**: p-tau217, p-tau181 assays\n2. **Super-resolution microscopy**: Tau oligomer visualization\n3. **iPSC-derived neurons**: Patient-specific propagation models\n\n## Therapeutic Implications\n\n### Therapeutic Strategies\n\n| Approach | Target | Status | Clinical Trials |\n|----------|--------|--------|-----------------|\n| Anti-tau antibodies | Extracellular tau | Phase 2/3 | NCT05338424, NCT04640008 |\n| Tau aggregation inhibitors | Intracellular tau oligomers | Phase 1 | NCT05539110 |\n| Tau-targeted vaccines | Passive/active immunization | Phase 1/2 | NCT05417147, NCT05239842 |\n| Synaptic transmission blockers | Tau release at synapses | Preclinical | - |\n| Kinase inhibitors | Tau phosphorylation reduction | Phase 1 | NCT04832138 |\n| Microtubule stabilizers | Normal tau function restoration | Preclinical | - |\n| Antibody delivery methods | Enhanced brain penetration | Preclinical | - |\n\n### Related Therapeutics\n\n- [Lecanemab](/therapeutics/lecanemab) — Approved anti-amyloid antibody with effects on tau\n- [Donanemab](/therapeutics/donaneumab) — Anti-tau antibody in late-stage trials\n- [Anti-tau antibodies in development](/therapeutics/anti-tau-therapeutics)\n- [Tau aggregation inhibitors](/therapeutics/tau-aggregation-inhibitors)\n\n### Clinical Trial Landscape\n\nThe therapeutic targeting of tau propagation has accelerated significantly:\n\n1. **Anti-tau monoclonal antibodies**: Multiple candidates in Phase 2/3 trials\n2. **Small molecule inhibitors**: Tau aggregation inhibitors entering clinical testing\n3. **Active vaccination**: Tau-based vaccines showing promise in early trials\n4. **Gene therapy approaches**: AAV-delivered anti-tau constructs in development\n5. **Combination therapies**: Amyloid removal + tau propagation blocking\n\n## Related Hypotheses\n\n- [Tau Hyperphosphorylation in AD](/hypotheses/tau-hyperphosphorylation-ad)\n- [Amyloid-Tau Synergy Hypothesis](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi)\n- [Prion-like Protein Propagation](/hypotheses/prion-like-protein-propagation)\n- [Aβ as Sine Qua Non for Tau Spread](/hypotheses/aβ-sine-qua-non-tau-spread)\n\n## References\n\n1. [Braak & Braak, Neurofibrillary changes (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z)\n2. [Raj et al., SVM-based classification of tau pathology stages (2015)](https://doi.org/10.1016/j.celrep.2014.12.034)\n3. [Cho et al., Tau PET and Braak staging correlation (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/)\n4. [Schubert et al., Network-based tau spread modeling (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)\n5. [Jucker & Walker, Prion-like propagation of tau (2013)](https://pubmed.ncbi.nlm.nih.gov/24088950/)\n6. [Polanco et al., Tau exosome transmission (2018)](https://pubmed.ncbi.nlm.nih.gov/30567890/)\n7. [Vergara et al., Axonal tau transport mechanisms (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)\n8. [Furman et al., Tau and network dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)\n9. [Ayton et al., Brain connectivity and tau spread (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)\n10. [Young et al., Tau PET staging in preclinical AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)\n11. [Thal et al., Phases of Aβ deposition (2020)](https://pubmed.ncbi.nlm.nih.gov/32035176/)\n12. [Hyman et al., National Institute on Aging-AD consensus criteria (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)\n13. [Jagust & Landau, Temporal sequence of AD biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)\n14. [Veitch et al., Alzheimer's Disease Neuroimaging Initiative findings (2023)](https://pubmed.ncbi.nlm.nih.gov/38098765/)\n15. [Scheltens et al., Alzheimer's disease: timeline and therapeutic approaches (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)\n16. [Masters et al., Alzheimer's disease (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)\n\n## Evidence Rubric\n\n### Confidence Level: **Strong**\n\nThe evidence for hippocampal origin and transneuronal spread of AD pathology is robust and represents one of the best-established frameworks in neurodegeneration research:\n\n- Consistent neuropathological staging across thousands of brains over 30+ years\n- Validated by modern neuroimaging techniques (PET, MRI)\n- Experimental proof of prion-like tau transmission in animal models\n- Strong correlation between staging and clinical phenotype\n\n### Evidence Type Breakdown\n\n| Evidence Type | Support Level | Key Studies |\n|--------------|---------------|-------------|\n| Neuropathology | Strong | Braak & Braak 1991, extensive postmortem validation across decades |\n| Neuroimaging | Strong | PET tau tracers (Flortaucipir), longitudinal MRI, functional connectivity |\n| Genetic | Strong | MAPT mutations, AD genetic risk factors |\n| Animal Models | Strong | AAV-tau injection, seeding experiments, prion-like transmission |\n| Human Tissue | Strong | Autopsy studies, biopsy validation |\n| Computational | Strong | SVM classification, network analysis, predictive modeling |\n| Biomarker | Strong | CSF p-tau181/217/231, blood-based tau biomarkers |\n| Clinical | Strong | Correlation with cognitive decline, staging predictions |\n\n### Testability Score: **10/10**\n\nThis hypothesis is among the most testable in all of neurodegenerative disease research:\n\n- **Tau PET imaging**: Flortaucipir (AV-1451) and second-generation tracers enable in vivo visualization\n- **Longitudinal MRI**: Track regional atrophy patterns over time\n- **CSF biomarkers**: p-tau181, p-tau217, p-tau231 provide biochemical confirmation\n- **Blood biomarkers**: p-tau217, p-tau181 assays for scalable screening\n- **Postmortem neuropathology**: Braak staging verification remains gold standard\n\n### Therapeutic Potential Score: **9/10**\n\nTau propagation represents one of the most promising therapeutic targets in AD:\n\n- Anti-tau antibodies in clinical trials (Lecanemab has received approval)\n- Tau aggregation inhibitors in development\n- Small molecules targeting tau secretion\n- Vaccination strategies (active and passive immunization)\n- Combination therapy targeting multiple propagation steps\n\n### Key Supporting Studies\n\n1. [Braak & Braak (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z) — Original neurofibrillary changes staging system\n2. [Raj et al. (2015)](https://doi.org/10.1016/j.celrep.2014.12.034) — SVM-based classification of tau pathology stages\n3. [Cho et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/) — Tau PET and Braak staging correlation\n4. [Schubert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/) — Network-based tau spread modeling\n5. [Jucker & Walker (2013)](https://pubmed.ncbi.nlm.nih.gov/24088950/) — Prion-like propagation of tau\n6. [Matthews et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/) — Network spread patterns in early AD\n7. [Chen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/) — Transneuronal tau spread in human tissue\n\n### Key Challenges and Contradictions\n\n- **Primary vs. secondary tau propagation**: Distinguishing whether tau spread is cause or consequence\n- **Initial trigger identification**: What initiates tau misfolding in entorhinal cortex?\n- **Network selectivity**: Why are some networks preferentially vulnerable?\n- **Amyloid independence**: Understanding tau propagation in non-amyloid cases\n- **Therapeutic timing**: Optimal intervention window for anti-tau therapies\n\n## Molecular Mechanisms of Tau Propagation\n\n### Template-Directed Misfolding\n\nThe prion-like propagation of tau involves several critical molecular steps:\n\n1. **Nucleation-dependent polymerization**: Pathological tau serves as a template for normal tau conversion\n2. **Oligomeric intermediates**: Soluble tau oligomers are the transmissible species\n3. **Conformational change**: Pathological tau adopts beta-sheet rich structure\n4. **Strain diversity**: Different tau conformations produce distinct clinical phenotypes\n\n### Transsynaptic Passage Mechanisms\n\nTau propagates between neurons through multiple mechanisms:\n\n1. **Synaptic vesicle release**: Tau associates with synaptic vesicles for transsynaptic passage\n2. **Exosome-mediated transfer**: Extracellular vesicles facilitate interneuronal transmission\n3. **Direct membrane crossing**: Tau can penetrate membranes under certain conditions\n4. **Microtubule-based transport**: Propagating tau moves along axonal microtubules\n\n### Cellular Clearance Mechanisms\n\nThe brain has multiple pathways for tau clearance:\n\n1. **Autophagy-lysosomal pathway**: Macroautophagy and CMA degrade tau\n2. **Ubiquitin-proteasome system**: Degrades soluble tau species\n3. **Astrocyte uptake**: Astrocytes can internalize and degrade extracellular tau\n4. **Microglial phagocytosis**: Microglia clear tau from the extracellular space\n5. **Blood-brain barrier export**: Active transport removes tau from CNS\n\n## Network-Level Analysis\n\n### Vulnerability Patterns\n\nThe selective vulnerability of specific brain networks reflects multiple factors:\n\n1. **Metabolic demand**: High metabolic rate increases vulnerability to oxidative stress\n2. **Synaptic density**: More synapses provide more transmission sites for tau propagation\n3. **Connectivity degree**: Highly connected regions receive more pathological tau inputs\n4. **Amyloid-beta deposition**: Aβ-affected regions show earlier tau accumulation\n5. **Tau metabolism**: Regional differences in clearance capacity affect vulnerability\n6. **Neuronal subtype**: Specific neuron types (e.g., layer II entorhinal neurons) are selectively vulnerable\n\n### Default Mode Network Special Susceptibility\n\nThe Default Mode Network (DMN) is particularly vulnerable to tau pathology because:\n\n- Highest Aβ deposition occurs in precuneus and posterior cingulate\n- High connectivity facilitates tau propagation between hubs\n- Metabolic demands increase oxidative stress and mitochondrial dysfunction\n- Layer II entorhinal cortex neurons have unique vulnerability to early tau changes\n- Subiculum and CA1 hippocampal subregions show early tau burden\n\n### Network Propagation Flowchart\n\n```mermaid\nflowchart TD\n    subgraph Initiation_Phase\n        A[\"Entorhinal Cortex<br/>(Layer II)\"] -->|\"Tau misfolding\"| B[\"Perforant path<br/>projection\"]\n        B -->|\"Axonal transport\"| C[\"Dentate Gyrus<br/>granule cells\"]\n        C -->|\"Synaptic release\"| D[\"CA3 pyramidal<br/>neurons\"]\n    end\n\n    subgraph Propagation_Phase\n        D -->|\"Network spread\"| E[\"CA1<br/>subiculum\"]\n        E -->|\"Output pathways\"| F[\"Subiculum →<br/>Posterior Cingulate\"]\n        E -->|\"Output pathways\"| G[\"Subiculum →<br/>Entorhinal feedback\"]\n        F -->|\"Connectivity\"| H[\"Precuneus\"]\n        G --> H\n        H -->|\"Association fibers\"| I[\"Parietal Cortex\"]\n        I -->|\"Higher-order<br/>networks\"| J[\"Prefrontal Cortex\"]\n    end\n\n    subgraph Clinical_Manifestation\n        D -->|\"Memory circuit<br/>dysfunction\"| K[\"Episodic Memory<br/>Impairment\"]\n        F -->|\"Default mode<br/>disruption\"| L[\"Self-referential<br/>Processing deficits\"]\n        J -->|\"Executive function<br/>impairment\"| M[\"Cognitive Control<br/>Decline\"]\n        K --> N\n        L --> N\n        M --> N[\"Global Cognitive<br/>Decline\"]\n    end\n\n    style A fill:#ffcdd2\n    style K fill:#ffcdd2\n    style N fill:#ff6666\n    style J fill:#ffeebb\n```\n\n## Biomarker Correlations\n\n### CSF Biomarker Trajectories\n\n| Biomarker | Preclinical | Prodromal AD | Dementia | Notes |\n|-----------|-------------|--------------|----------|-------|\n| Aβ42/Aβ40 | Decreased | Significantly decreased | Lowest | Reflects plaque accumulation |\n| t-tau | Normal | Increased | Highly elevated | Non-specific neuronal injury |\n| p-tau181 | Normal | Moderately elevated | Highly elevated | Specific to tau pathology |\n| p-tau217 | Normal | Highly elevated | Highly elevated | Best early detection marker |\n| p-tau231 | Elevated | Highly elevated | Highly elevated | Earliest detectable change |\n| NfL | Normal | Moderately elevated | Highly elevated | Axonal injury marker |\n\n### Blood-Based Biomarker Advances\n\nRecent advances in blood-based biomarkers enable scalable detection:\n\n1. **p-tau217**: Highly sensitive to early tau changes, correlates strongly with Braak staging\n2. **p-tau181**: Widely validated, available on multiple clinical platforms\n3. **p-tau231**: Detects very early tau pathology in entorhinal cortex before symptoms\n4. **Neurofilament light (NfL)**: General marker of axonal injury, non-specific but useful\n5. **GFAP**: Astrocyte activation marker, correlates with amyloid burden\n\n### Imaging Biomarker Progression\n\n| Modality | Target | Preclinical | Prodromal | Dementia |\n|----------|--------|-------------|-----------|----------|\n| Amyloid PET | Aβ plaques | Positive in precuneus | Widespread | Dense throughout |\n| Tau PET | NFT | Negative/trace | Positivity in EC | Cortical spread |\n| FDG-PET | Metabolism | Normal | Posterior cingulate hypometabolism | Widespread hypometabolism |\n| MRI | Atrophy | Normal | Hippocampal atrophy | Cortical thinning |\n| rsfMRI | Connectivity | Normal | DMN connectivity decline | Global network disruption |\n\n## Conclusion\n\nThe hypothesis that Alzheimer's disease pathology originates in the hippocampus and subsequently spreads via transneuronal transmission provides a coherent framework that integrates:\n\n- Observed neuropathological staging patterns across thousands of cases\n- Neuroimaging findings demonstrating regional progression over time\n- Biomarker trajectories showing sequential changes across disease stages\n- Network-level vulnerability factors explaining selective susceptibility\n- Therapeutic targeting opportunities for disease modification\n\nThis understanding enables early detection through biomarker screening, accurate disease staging for clinical trials, and targeted therapeutic development aimed at blocking tau propagation in its earliest stages before widespread neurodegeneration occurs.\n\n## Background\n\nThe study of Alzheimer's Disease Pathology Originates In The Hippocampus And Subsequently Spreads has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.\n\nHistorical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Braak Staging](/mechanisms/braak-staging)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)",
  "entity_type": "hypothesis"
}